3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
70
Squamous Cell Carcinoma of Head and Neck
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
30
Lung Neoplasms
28
Melanoma
24
Triple Negative Breast Neoplasms
23
Neoplasms
20
Neoplasm Metastasis
20
Breast Neoplasms
19
Colorectal Neoplasms
18
Head and Neck Neoplasms
15
Endometrial Neoplasms
15
Ovarian Neoplasms
14
Carcinoma, Renal Cell
13
Urinary Bladder Neoplasms
11
Carcinoma, Transitional Cell
10
Pancreatic Neoplasms
7
Hodgkin Disease
7
Esophageal Neoplasms
7
Uterine Cervical Neoplasms
6
Sarcoma
6
Recurrence
6
Lymphoma
6
Carcinoma
6
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Prostatic Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Interventions
venetoclax
6
ibrutinib
4
pirtobrutinib
2
Sirolimus
2
Rituximab
2
Mycophenolic Acid
2
Cyclosporine
2
Cyclophosphamide
2
zanubrutinib
1
pembrolizumab
1
loncastuximab tesirine
1
fludarabine phosphate
1
carfilzomib
1
acalabrutinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Specimen Handling
1
Rifaximin
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Dexamethasone
1
Cyclosporins
1
Calcium Dobesilate
1
CT-P10
1
Busulfan
1
Biopsy
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
pembrolizumab
×
30 days
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts